Trial · NCT03492840
Treatment of Women With Lipedema Involving Substantial Fat Knee of Women and Men With Nodular Dercum's Disease
NCT03492840, Phase 2, Completed, Raziel Therapeutics Ltd.; results first posted 2024-02-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treatment of Women With Lipedema Involving Substantial Fat Knee of Women and Men With Nodular Dercum's Disease. Trials, record NCT03492840. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03492840
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment of Women With Lipedema Involving Substantial Fat Knee of Women and Men With Nodular Dercum's Disease
- NCT number
- NCT03492840
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 12 participants, actual
- Lead sponsor
- Raziel Therapeutics Ltd.
- Conditions
- Lipedema, Dercum Disease
- Interventions
- RZL-012
- First posted
- 2018-04-10
- Last updated
- 2024-02-08
- Results first posted
- 2024-02-08
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Incidence of Any Grade 3 or Greater Event Intolerable Side Effect Experienced in a Cohort | 0-14 days | Trial will proceed as long as no more than one subject experiences an intolerable side effect in a cohort |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Incidence of Any Grade 3 or Greater Event Intolerable Side Effect Experienced in a Cohort | 0-14 days | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Incidence of Any Grade 3 or Greater Event Intolerable Side Effect Experienced in a Cohort | Cohort 1 - Dercum's Disease | 0 | Participants | ||
| The Incidence of Any Grade 3 or Greater Event Intolerable Side Effect Experienced in a Cohort | Cohort 2 - Lipedema 60mg | 0 | Participants | ||
| The Incidence of Any Grade 3 or Greater Event Intolerable Side Effect Experienced in a Cohort | Cohort 2 Lipedema 80mg | 0 | Participants |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cohort 1 - Dercum's Disease | 6 | |
| Overall Study | STARTED | Cohort 2 - Lipedema 60mg | 3 | |
| Overall Study | STARTED | Cohort 2 Lipedema 80mg | 3 | |
| Overall Study | COMPLETED | Cohort 1 - Dercum's Disease | 6 | |
| Overall Study | COMPLETED | Cohort 2 - Lipedema 60mg | 3 | |
| Overall Study | COMPLETED | Cohort 2 Lipedema 80mg | 3 | |
| Overall Study | NOT COMPLETED | Cohort 1 - Dercum's Disease | 0 | |
| Overall Study | NOT COMPLETED | Cohort 2 - Lipedema 60mg | 0 | |
| Overall Study | NOT COMPLETED | Cohort 2 Lipedema 80mg | 0 |
Source ClinicalTrials.gov
Adverse events15
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Injection site pain | General disorders | Cohort 1 - Dercum's Disease | 2 | 6 | |
| other | Injection site pain | General disorders | Cohort 2 - Lipedema 60 mg | 2 | 3 | |
| other | Injection site pain | General disorders | Cohort 2 - Lipedema 80 mg | 1 | 3 | |
| other | pain | General disorders | Cohort 1 - Dercum's Disease | 2 | 6 | |
| other | pain | General disorders | Cohort 2 - Lipedema 60 mg | 1 | 3 | |
| other | pain | General disorders | Cohort 2 - Lipedema 80 mg | 1 | 3 | |
| other | Headache | Nervous system disorders | Cohort 1 - Dercum's Disease | 1 | 6 | |
| other | Headache | Nervous system disorders | Cohort 2 - Lipedema 60 mg | 1 | 3 | |
| other | Headache | Nervous system disorders | Cohort 2 - Lipedema 80 mg | 1 | 3 | |
| other | Contusion | Injury, poisoning and procedural complications | Cohort 1 - Dercum's Disease | 1 | 6 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cohort 1 - Dercum's Disease | 0 | 6 |
| Total, all-cause mortality | Cohort 2 - Lipedema 60 mg | 0 | 3 |
| Total, all-cause mortality | Cohort 2 - Lipedema 80 mg | 0 | 3 |
| Total, other adverse events | Cohort 1 - Dercum's Disease | 6 | 6 |
| Total, other adverse events | Cohort 2 - Lipedema 60 mg | 3 | 3 |
| Total, other adverse events | Cohort 2 - Lipedema 80 mg | 3 | 3 |
| Total, serious adverse events | Cohort 1 - Dercum's Disease | 0 | 6 |
| Total, serious adverse events | Cohort 2 - Lipedema 60 mg | 0 | 3 |
| Total, serious adverse events | Cohort 2 - Lipedema 80 mg | 0 | 3 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03492840
GET https://conductscience.org/api/trials/v1/NCT03492840/registered